4-HO-MALT

  1. Home
  2. Wiki
4-HO-MALT
Clinical data
Other names4-OH-MALT; 4-Hydroxy-N-methyl-N-allyltryptamine; Maltocin; Malocin
Routes of
administration		Oral
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • 3-[2-[methyl(prop-2-enyl)amino]ethyl]-1H-indol-4-ol
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H18N2O
Molar mass230.311 g·mol−1
3D model (JSmol)
  • CN(CCC1=CNC2=C1C(=CC=C2)O)CC=C
  • InChI=1S/C14H18N2O/c1-3-8-16(2)9-7-11-10-15-12-5-4-6-13(17)14(11)12/h3-6,10,15,17H,1,7-9H2,2H3
  • Key:NWEWNVPCYZONHK-UHFFFAOYSA-N

4-HO-MALT, also known as 4-hydroxy-N-methyl-N-allyltryptamine or as maltocin, is a tryptamine derivative related to 4-HO-DALT (dalocin) which has been sold as a designer drug, first being detected in Slovenia in 2021.[1][2]

Interactions

[edit]
See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]

4-HO-MALT acts as an agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[3] It also interacts with other serotonin receptors. The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[3]

See also

[edit]

References

[edit]
  1. ^ Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, McCorvy JD, Halberstadt AL (April 2021). "Investigation of the Structure-Activity Relationships of Psilocybin Analogues". ACS Pharmacology & Translational Science. 4 (2): 533–542. doi:10.1021/acsptsci.0c00176. PMC 8033608. PMID 33860183.
  2. ^ European Monitoring Centre for Drugs and Drug Addiction. (June 2022). New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System (PDF). European Monitoring Centre for Drugs and Drug Addiction. doi:10.2810/882318 (inactive 1 July 2025). ISBN 978-92-9497-737-3.{{cite book}}: CS1 maint: DOI inactive as of July 2025 (link)
  3. ^ a b Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, McCorvy JD, Halberstadt AL (April 2021). "Investigation of the Structure-Activity Relationships of Psilocybin Analogues". ACS Pharmacol Transl Sci. 4 (2): 533–542. doi:10.1021/acsptsci.0c00176. PMC 8033608. PMID 33860183.
[edit]